HU199694B - Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives - Google Patents

Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives Download PDF

Info

Publication number: HU199694B
Authority: HU; Hungary
Prior art keywords: gnrh; group; hormone; treatment; leucyl
Prior art date: 1988-05-10

Application number

HU882347A

Other languages

English (en)

Hungarian (hu)

Other versions

HUT49813A (en

Inventor

Gyoergy Keri

Istvan Teplan

Tamas Gulyas

Balazs Szoeke

Robert J Nicholson

Istvanne Boekoenyi

Aniko Horvath

Orsolya Csuka

Original Assignee

Innofinance Altalanos Innovaci

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-05-10

Filing date

1988-05-10

Publication date

1990-03-28

1988-05-10 Application filed by Innofinance Altalanos Innovaci filed Critical Innofinance Altalanos Innovaci

1988-05-10 Priority to HU882347A priority Critical patent/HU199694B/hu

1989-04-18 Priority to IL89998A priority patent/IL89998A0/xx

1989-05-08 Priority to CH1725/89A priority patent/CH678013A5/de

1989-05-09 Priority to NL8901159A priority patent/NL8901159A/nl

1989-05-10 Priority to DK228289A priority patent/DK228289A/da

1989-05-10 Priority to GR890100315A priority patent/GR890100315A/el

1989-05-10 Priority to JP1115265A priority patent/JPH0215097A/ja

1989-05-10 Priority to LU87516A priority patent/LU87516A1/fr

1989-05-10 Priority to KR1019890006230A priority patent/KR900017610A/ko

1989-05-10 Priority to FR8906094A priority patent/FR2631237A1/fr

1989-05-10 Priority to DE3915317A priority patent/DE3915317A1/de

1989-05-10 Priority to GB8910724A priority patent/GB2218335B/en

1989-05-10 Priority to FI892275A priority patent/FI892275A7/fi

1989-05-10 Priority to SE8901660A priority patent/SE8901660L/

1989-05-10 Priority to BE8900499A priority patent/BE1004932A3/fr

1989-05-11 Priority to IT8920435A priority patent/IT1229251B/it

1989-11-28 Publication of HUT49813A publication Critical patent/HUT49813A/hu

1990-03-28 Publication of HU199694B publication Critical patent/HU199694B/hu

Links

238000000034 method Methods 0.000 title claims description 12
239000008194 pharmaceutical composition Substances 0.000 title claims description 11
108050000048 Gonadoliberin Proteins 0.000 title claims description 9
102000009165 Gonadoliberin Human genes 0.000 title claims description 9
230000008569 process Effects 0.000 title claims description 7
238000011282 treatment Methods 0.000 claims description 20
206010028980 Neoplasm Diseases 0.000 claims description 19
229940088597 hormone Drugs 0.000 claims description 14
239000005556 hormone Substances 0.000 claims description 14
230000001419 dependent effect Effects 0.000 claims description 11
239000004480 active ingredient Substances 0.000 claims description 6
230000003054 hormonal effect Effects 0.000 claims description 6
125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 claims description 4
125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 claims description 4
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 4
230000001939 inductive effect Effects 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical group CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 2
125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 claims description 2
150000007513 acids Chemical class 0.000 claims description 2
150000004696 coordination complex Chemical class 0.000 claims description 2
BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims description 2
125000001998 leucyl group Chemical group 0.000 claims description 2
239000002184 metal Chemical class 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
125000001982 tryptophyl group Chemical group 0.000 claims description 2
ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 claims 1
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 24
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 13
206010006187 Breast cancer Diseases 0.000 description 12
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 12
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 12
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
229940028334 follicle stimulating hormone Drugs 0.000 description 12
208000026310 Breast neoplasm Diseases 0.000 description 11
230000000694 effects Effects 0.000 description 10
230000002611 ovarian Effects 0.000 description 10
230000016087 ovulation Effects 0.000 description 10
241001465754 Metazoa Species 0.000 description 9
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 9
235000019688 fish Nutrition 0.000 description 8
150000003431 steroids Chemical class 0.000 description 8
241000251468 Actinopterygii Species 0.000 description 7
230000006870 function Effects 0.000 description 7
230000010534 mechanism of action Effects 0.000 description 7
238000000586 desensitisation Methods 0.000 description 6
230000003325 follicular Effects 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
239000000203 mixture Substances 0.000 description 6
229960003387 progesterone Drugs 0.000 description 6
239000000186 progesterone Substances 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
230000004614 tumor growth Effects 0.000 description 6
ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
230000000259 anti-tumor effect Effects 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 5
210000001672 ovary Anatomy 0.000 description 5
230000009467 reduction Effects 0.000 description 5
NMJREATYWWNIKX-XJIZABAQSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 NMJREATYWWNIKX-XJIZABAQSA-N 0.000 description 4
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
241000287828 Gallus gallus Species 0.000 description 4
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
239000000556 agonist Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
229960005309 estradiol Drugs 0.000 description 4
229930182833 estradiol Natural products 0.000 description 4
238000009472 formulation Methods 0.000 description 4
230000002710 gonadal effect Effects 0.000 description 4
230000035800 maturation Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
WPKQYFUSPONRAT-BXXNOCLASA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-5-amino-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hy Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 WPKQYFUSPONRAT-BXXNOCLASA-N 0.000 description 3
102000006771 Gonadotropins Human genes 0.000 description 3
108010086677 Gonadotropins Proteins 0.000 description 3
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 3
108010069236 Goserelin Proteins 0.000 description 3
206010062767 Hypophysitis Diseases 0.000 description 3
229940011871 estrogen Drugs 0.000 description 3
239000000262 estrogen Substances 0.000 description 3
210000002149 gonad Anatomy 0.000 description 3
239000002622 gonadotropin Substances 0.000 description 3
229940094892 gonadotropins Drugs 0.000 description 3
230000012010 growth Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
230000001817 pituitary effect Effects 0.000 description 3
210000003635 pituitary gland Anatomy 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
230000027272 reproductive process Effects 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
229940104230 thymidine Drugs 0.000 description 3
241000271566 Aves Species 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
241000700159 Rattus Species 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
201000008275 breast carcinoma Diseases 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
210000004246 corpus luteum Anatomy 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
210000004907 gland Anatomy 0.000 description 2
239000003163 gonadal steroid hormone Substances 0.000 description 2
230000001456 gonadotroph Effects 0.000 description 2
238000010562 histological examination Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
230000021616 negative regulation of cell division Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
229960003604 testosterone Drugs 0.000 description 2
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
102000005606 Activins Human genes 0.000 description 1
108010059616 Activins Proteins 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
206010060999 Benign neoplasm Diseases 0.000 description 1
208000005243 Chondrosarcoma Diseases 0.000 description 1
MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
125000002436 D-phenylalanyl group Chemical group N[C@@H](C(=O)*)CC1=CC=CC=C1 0.000 description 1
125000000734 D-serino group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
102000008175 FSH Receptors Human genes 0.000 description 1
108010060374 FSH Receptors Proteins 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
102000023108 LH Receptors Human genes 0.000 description 1
108010011942 LH Receptors Proteins 0.000 description 1
102000008238 LHRH Receptors Human genes 0.000 description 1
108010021290 LHRH Receptors Proteins 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
108010085012 Steroid Receptors Proteins 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000035622 drinking Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
102000015694 estrogen receptors Human genes 0.000 description 1
108010038795 estrogen receptors Proteins 0.000 description 1
210000001752 female genitalia Anatomy 0.000 description 1
230000008217 follicular development Effects 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
101150108262 gnrh1 gene Proteins 0.000 description 1
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000003581 hormone blood level Effects 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
230000000624 ovulatory effect Effects 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
230000004800 psychological effect Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000003578 releasing effect Effects 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
208000012201 sexual and gender identity disease Diseases 0.000 description 1
208000015891 sexual disease Diseases 0.000 description 1
238000005549 size reduction Methods 0.000 description 1
239000000243 solution Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000021595 spermatogenesis Effects 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
102000005969 steroid hormone receptors Human genes 0.000 description 1
230000010009 steroidogenesis Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
229940033942 zoladex Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)

HU882347A 1988-05-10 1988-05-10 Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives HU199694B (en)

Priority Applications (16)

Application Number	Priority Date	Filing Date	Title
HU882347A HU199694B (en)	1988-05-10	1988-05-10	Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives
IL89998A IL89998A0 (en)	1988-05-10	1989-04-18	Use of gonadoliberin derivatives in the treatment of tumours
CH1725/89A CH678013A5 (fr)	1988-05-10	1989-05-08
NL8901159A NL8901159A (nl)	1988-05-10	1989-05-09	Toepassing van gonadoliberinederivaten voor de bereiding van tumor-remmende farmaceutische preparaten.
DK228289A DK228289A (da)	1988-05-10	1989-05-10	Anvendelse af gonadoliberinderivater ved fremstilling af laegemidler til behandling af svulster
GR890100315A GR890100315A (el)	1988-05-10	1989-05-10	Χρηση παραγωγων γκοναντολιμπερινης δια την παρασκευη φαρμακευτικων αντικαρκινικων συνθεσεων.
JP1115265A JPH0215097A (ja)	1988-05-10	1989-05-10	ゴナドリベリン誘導体含有薬剤の製造方法及びその使用方法
LU87516A LU87516A1 (fr)	1988-05-10	1989-05-10	Utilisation de derives de la gonadoliberine pour preparer des compositions pharmaceutiques anti-tumorales
KR1019890006230A KR900017610A (ko)	1988-05-10	1989-05-10	고나돌리베린 유도체를 함유하는 종양억제용 약제조성물의 제조방법
FR8906094A FR2631237A1 (fr)	1988-05-10	1989-05-10	Utilisation de derives de la gonadoliberine pour preparer des compositions pharmaceutiques anti-tumorales
DE3915317A DE3915317A1 (de)	1988-05-10	1989-05-10	Verwendung von gonadoliberinderivaten
GB8910724A GB2218335B (en)	1988-05-10	1989-05-10	Use of gonadoliberin derivatives for preparing tumour-inhibiting medicaments
FI892275A FI892275A7 (fi)	1988-05-10	1989-05-10	Foerfarande foer framstaellning av tumoerhaemmande kompositioner innehaollande gonadoliberinderivat.
SE8901660A SE8901660L (sv)	1988-05-10	1989-05-10	Anvaendning av gonadoliberinderivat foer fram- staellning av tumoerinhiberande farmaceutiska kompositioner
BE8900499A BE1004932A3 (fr)	1988-05-10	1989-05-10	Utilisation de derives de la gonadoliberine pour preparer des compositions pharmaceutiques anti-tumorales.
IT8920435A IT1229251B (it)	1988-05-10	1989-05-11	Impiego di derivati della gonadoliberina per preparare composizioni farmaceutiche inibenti tumori

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU882347A HU199694B (en)	1988-05-10	1988-05-10	Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives

Publications (2)

Publication Number	Publication Date
HUT49813A HUT49813A (en)	1989-11-28
HU199694B true HU199694B (en)	1990-03-28

Family

ID=10958948

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU882347A HU199694B (en)	1988-05-10	1988-05-10	Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives

Country Status (16)

Country	Link
JP (1)	JPH0215097A (fr)
KR (1)	KR900017610A (fr)
BE (1)	BE1004932A3 (fr)
CH (1)	CH678013A5 (fr)
DE (1)	DE3915317A1 (fr)
DK (1)	DK228289A (fr)
FI (1)	FI892275A7 (fr)
FR (1)	FR2631237A1 (fr)
GB (1)	GB2218335B (fr)
GR (1)	GR890100315A (fr)
HU (1)	HU199694B (fr)
IL (1)	IL89998A0 (fr)
IT (1)	IT1229251B (fr)
LU (1)	LU87516A1 (fr)
NL (1)	NL8901159A (fr)
SE (1)	SE8901660L (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5760000A (en) *	1994-05-13	1998-06-02	University Technologies International,Inc.	Inhibition of liver cancer by the use of GnRH and GnRH analogs
US6054432A (en) *	1996-09-12	2000-04-25	Asta Medica Aktiengesellschaft	Means for treating prostate hypertrophy and prostate cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4410514A (en) *	1982-12-06	1983-10-18	The Salk Institute For Biological Studies	GnRH Agonists
IT1178775B (it) *	1983-12-23	1987-09-16	Konzponti Valto Es Hitelbank R	Derivati della gonadoliberina e procedimento per la loro preparazione
HU189394B (en) *	1983-12-23	1986-06-30	Koezponti Valto- Es Hitelbank Rt Innovacios Alap,Hu	Method for producing spermatozoa suitable for fertilization from mature fishes
US4760053A (en) *	1984-08-02	1988-07-26	Fernand Labrie	Combination therapy for selected sex steroid dependent cancers
DE3586053D1 (de) *	1984-08-02	1992-06-17	Labrie	Pharmazeutische zusammensetzung fuer die kombinationstherapie von hormonabhaengigem krebs.
HU193607B (en) *	1985-07-18	1987-11-30	Innofinance Altalanos Innovaci	Process for production of sexual products applyable for natural or artificial insemination for mammates
US4721775A (en) *	1985-08-26	1988-01-26	Board Of Regents, The University Of Texas System	Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
HU194913B (en) *	1986-01-03	1988-03-28	Innofinance Altalanos Innovaci	Process for producing novel gonadoliberin derivatives containing in the sixth position aromatic amino carboxylic acid and medical preparations containing these compounds

1988
- 1988-05-10 HU HU882347A patent/HU199694B/hu active IP Right Revival
1989
- 1989-04-18 IL IL89998A patent/IL89998A0/xx unknown
- 1989-05-08 CH CH1725/89A patent/CH678013A5/de not_active IP Right Cessation
- 1989-05-09 NL NL8901159A patent/NL8901159A/nl not_active Application Discontinuation
- 1989-05-10 DK DK228289A patent/DK228289A/da not_active Application Discontinuation
- 1989-05-10 DE DE3915317A patent/DE3915317A1/de not_active Withdrawn
- 1989-05-10 FI FI892275A patent/FI892275A7/fi not_active Application Discontinuation
- 1989-05-10 KR KR1019890006230A patent/KR900017610A/ko not_active Withdrawn
- 1989-05-10 LU LU87516A patent/LU87516A1/fr unknown
- 1989-05-10 JP JP1115265A patent/JPH0215097A/ja active Pending
- 1989-05-10 GR GR890100315A patent/GR890100315A/el unknown
- 1989-05-10 FR FR8906094A patent/FR2631237A1/fr active Pending
- 1989-05-10 SE SE8901660A patent/SE8901660L/ not_active Application Discontinuation
- 1989-05-10 BE BE8900499A patent/BE1004932A3/fr not_active IP Right Cessation
- 1989-05-10 GB GB8910724A patent/GB2218335B/en not_active Expired - Fee Related
- 1989-05-11 IT IT8920435A patent/IT1229251B/it active

Also Published As

Publication number	Publication date
IT1229251B (it)	1991-07-26
GR890100315A (el)	1990-03-12
HUT49813A (en)	1989-11-28
CH678013A5 (fr)	1991-07-31
DK228289A (da)	1989-11-11
GB2218335A (en)	1989-11-15
BE1004932A3 (fr)	1993-03-02
IL89998A0 (en)	1989-12-15
SE8901660D0 (sv)	1989-05-10
NL8901159A (nl)	1989-12-01
JPH0215097A (ja)	1990-01-18
DE3915317A1 (de)	1989-11-23
FI892275A7 (fi)	1989-11-11
DK228289D0 (da)	1989-05-10
FI892275A0 (fi)	1989-05-10
FR2631237A1 (fr)	1989-11-17
LU87516A1 (fr)	1990-12-11
SE8901660L (sv)	1989-11-11
GB8910724D0 (en)	1989-06-28
GB2218335B (en)	1991-09-25
KR900017610A (ko)	1990-12-19
IT8920435A0 (it)	1989-05-11

Legal Events

Date	Code	Title	Description
1990-06-28	HU90	Patent valid on 900628
1994-02-28	HMM4	Cancellation of final prot. due to non-payment of fee
1995-05-29	HPC4	Succession in title of patentee	Owner name: SALAMON BERKOWITZ, HU
1997-02-28	HMM4	Cancellation of final prot. due to non-payment of fee
1997-04-28	DNF4	Restoration of lapsed final protection
1997-11-28	HPC4	Succession in title of patentee	Owner name: SALAMON AND COMPANY INC., UA

Publication	Publication Date	Title
Corbin	1982	From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents
Reissmann et al.	2000	The LHRH antagonist cetrorelix: a review
Emons et al.	1993	High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines
Blankenstein et al.	1985	Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells
Lin et al.	1988	Effects of [d-Arg6, Trp7, Leu8, Pro9 NEt]-luteinizing hormone-releasing hormone (sGnRH-A) and [d-Ala6, Pro9NEt]-luteinizing hormone-releasing hormone (LHRH-A), in combination with pimozide or domperidone, on Gonadotropin release and ovulation in the Chinese loach and common carp
JPH01502265A (ja)	1989-08-10	避妊薬用としての性ステロイド放出と組合わされた黄体形成ホルモン放出ホルモン組成物の連続放出
Furr et al.	1982	Use of analogues of luteinizing hormone-releasing hormone for the treatment of cancer
Taylor et al.	1989	Testosterone in a cyclodextrin-containing formulation: behavioral and physiological effects of episode-like pulses in rats
TW577735B (en)	2004-03-01	Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders
Yano et al.	1992	Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH
Klijn et al.	1984	Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer
Welsch et al.	1977	17β-oestradiol and Enovid mammary tumorigenesis in C3H/HeJ female mice: counteraction by concurrent 2-bromo-α-ergocryptine
Ahluwalia et al.	1970	Effects of exogenous hormones on the male reproductive organs of vitamin A-deficient rats
CZ15097A3 (en)	1997-11-12	Method of adjusting tonic secretion of ovarial estrogen for long-term therapeutical regimes
Korkut et al.	1991	Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
US20120004182A1 (en)	2012-01-05	Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells
Rose et al.	1979	Modification of the effect of a gonadoliberin analog on 7, 12-dimethylbenz (a) anthracene-induced rat mammary tumors by hormone replacement
HU199694B (en)	1990-03-28	Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives
Reissmann et al.	1992	Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone
WO2002039995A2 (fr)	2002-05-23	Traitement combine de maladies dependantes des oestrogenes
WO2002039996A2 (fr)	2002-05-23	Therapie combinee contre des tumeurs comprenant du phosphate d'estramustine et des agonistes ou antagonistes de lh-rh
Reissmann et al.	1996	Pharmacological studies with cetrorelix (SB-75), a potent antagonist of luteinising hormone-releasing hormone
Tominaga et al.	1990	Effect of CGS 16949A plus tamoxifen on induced mammary tumours in rats
Nicholson et al.	1992	Antitumour Activity of Folligen, a Novel Gonadotropin-Releasing Hormone Analogue against DMBA Induced Tumours in the Rat
Forti	1988	Clinicai applications of GnRH analogs